278 related articles for article (PubMed ID: 38257366)
21. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
22. Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity.
Zhong Z; Zhang M; Ning Y; Mao G; Li X; Deng Q; Chen X; Zuo D; Zhao X; Xie E; Wang H; Guo L; Li B; Xiao K; He X
Sci Rep; 2022 Oct; 12(1):18011. PubMed ID: 36289396
[TBL] [Abstract][Full Text] [Related]
23. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.
Hou W; Yuan Q; Yuan X; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2019 Oct; 37(5):876-889. PubMed ID: 30511201
[TBL] [Abstract][Full Text] [Related]
24. FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
Lakins MA; Koers A; Giambalvo R; Munoz-Olaya J; Hughes R; Goodman E; Marshall S; Wollerton F; Batey S; Gliddon D; Tuna M; Brewis N
Clin Cancer Res; 2020 Aug; 26(15):4154-4167. PubMed ID: 32345647
[TBL] [Abstract][Full Text] [Related]
25. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
[TBL] [Abstract][Full Text] [Related]
26. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
[TBL] [Abstract][Full Text] [Related]
27. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
28. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
29. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
[TBL] [Abstract][Full Text] [Related]
30. Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.
Park JA; Cheung NV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086947
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
32. Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232.
Villa-Ruano N; Guerrero-González T; Gómez-Conde E; Perez-Santos M
Expert Opin Ther Pat; 2020 Oct; 30(10):723-727. PubMed ID: 32787475
[TBL] [Abstract][Full Text] [Related]
33. A Bispecific Modeling Framework Enables the Prediction of Efficacy, Toxicity, and Optimal Molecular Design of Bispecific Antibodies Targeting MerTK.
Li R; Dere E; Kwong M; Fei M; Dave R; Masih S; Wang J; McNamara E; Huang H; Liang WC; Schutt L; Kamath AV; Ovacik MA
AAPS J; 2024 Jan; 26(1):11. PubMed ID: 38167740
[TBL] [Abstract][Full Text] [Related]
34. Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.
Hellmann MD; Bivi N; Calderon B; Shimizu T; Delafontaine B; Liu ZT; Szpurka AM; Copeland V; Hodi FS; Rottey S; Aftimos P; Piao Y; Gandhi L; Galvao VR; Leow CC; Doi T
Clin Cancer Res; 2021 May; 27(10):2773-2781. PubMed ID: 33441294
[TBL] [Abstract][Full Text] [Related]
35. Specific targeting immunotherapy of cancer with bispecific antibodies.
Kudo T; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Kodama H; Ichiyama M; Takemura S; Yoshida H; Saeki H; Saijyo S; Takahashi J; Tominaga T; Matsuno S
Tohoku J Exp Med; 1999 Aug; 188(4):275-88. PubMed ID: 10598685
[TBL] [Abstract][Full Text] [Related]
36. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
[TBL] [Abstract][Full Text] [Related]
37. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
38. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
39. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
[TBL] [Abstract][Full Text] [Related]
40. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
